These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17766459)

  • 61. Probiotic engineering strategies for the heterologous production of antimicrobial peptides.
    Mejía-Pitta A; Broset E; de la Fuente-Nunez C
    Adv Drug Deliv Rev; 2021 Sep; 176():113863. PubMed ID: 34273423
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recipe for Success: Suggestions and Recommendations for the Isolation and Characterisation of Bacteriocins.
    Twomey E; Hill C; Field D; Begley M
    Int J Microbiol; 2021; 2021():9990635. PubMed ID: 34257667
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic Application of Lantibiotics and Other Lanthipeptides: Old and New Findings.
    van Staden ADP; van Zyl WF; Trindade M; Dicks LMT; Smith C
    Appl Environ Microbiol; 2021 Jun; 87(14):e0018621. PubMed ID: 33962984
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The manifold roles of microbial ribosomal peptide-based natural products in physiology and ecology.
    Li Y; Rebuffat S
    J Biol Chem; 2020 Jan; 295(1):34-54. PubMed ID: 31784450
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Deciphering the interplay between the genotoxic and probiotic activities of Escherichia coli Nissle 1917.
    Massip C; Branchu P; Bossuet-Greif N; Chagneau CV; Gaillard D; Martin P; Boury M; Sécher T; Dubois D; Nougayrède JP; Oswald E
    PLoS Pathog; 2019 Sep; 15(9):e1008029. PubMed ID: 31545853
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Benefits and Inputs From Lactic Acid Bacteria and Their Bacteriocins as Alternatives to Antibiotic Growth Promoters During Food-Animal Production.
    Vieco-Saiz N; Belguesmia Y; Raspoet R; Auclair E; Gancel F; Kempf I; Drider D
    Front Microbiol; 2019; 10():57. PubMed ID: 30804896
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Engineered E. coli Nissle 1917 for the reduction of vancomycin-resistant
    Geldart KG; Kommineni S; Forbes M; Hayward M; Dunny GM; Salzman NH; Kaznessis YN
    Bioeng Transl Med; 2018 Sep; 3(3):197-208. PubMed ID: 30377660
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Review: The Fate of Bacteriocins in the Human Gastro-Intestinal Tract: Do They Cross the Gut-Blood Barrier?
    Dicks LMT; Dreyer L; Smith C; van Staden AD
    Front Microbiol; 2018; 9():2297. PubMed ID: 30323796
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antimicrobial activity of lactic acid bacteria in dairy products and gut: effect on pathogens.
    Arqués JL; Rodríguez E; Langa S; Landete JM; Medina M
    Biomed Res Int; 2015; 2015():584183. PubMed ID: 25861634
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cationic antimicrobial polymers and their assemblies.
    Carmona-Ribeiro AM; de Melo Carrasco LD
    Int J Mol Sci; 2013 May; 14(5):9906-46. PubMed ID: 23665898
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anti-infective properties of bacteriocins: an update.
    Hammami R; Fernandez B; Lacroix C; Fliss I
    Cell Mol Life Sci; 2013 Aug; 70(16):2947-67. PubMed ID: 23109101
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New horizons for host defense peptides and lantibiotics.
    Dawson MJ; Scott RW
    Curr Opin Pharmacol; 2012 Oct; 12(5):545-50. PubMed ID: 22776251
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Probiotics and gastrointestinal disease: successes, problems and future prospects.
    Culligan EP; Hill C; Sleator RD
    Gut Pathog; 2009 Nov; 1(1):19. PubMed ID: 19930635
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fate and efficacy of lacticin 3147-producing Lactococcus lactis in the mammalian gastrointestinal tract.
    Dobson A; Crispie F; Rea MC; O'Sullivan O; Casey PG; Lawlor PG; Cotter PD; Ross P; Gardiner GE; Hill C
    FEMS Microbiol Ecol; 2011 Jun; 76(3):602-14. PubMed ID: 21314706
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmaceutical design of a delivery system for the bacteriocin lacticin 3147.
    Ryan A; Patel P; O'Connor PM; Ross RP; Hill C; Hudson SP
    Drug Deliv Transl Res; 2021 Aug; 11(4):1735-1751. PubMed ID: 33876405
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bioavailability of the anti-clostridial bacteriocin thuricin CD in gastrointestinal tract.
    Rea MC; Alemayehu D; Casey PG; O'Connor PM; Lawlor PG; Walsh M; Shanahan F; Kiely B; Ross RP; Hill C
    Microbiology (Reading); 2014 Feb; 160(Pt 2):439-445. PubMed ID: 24287693
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The biology of lantibiotics from the lacticin 481 group is coming of age.
    Dufour A; Hindré T; Haras D; Le Pennec JP
    FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fate of the two-component lantibiotic lacticin 3147 in the gastrointestinal tract.
    Gardiner GE; Rea MC; O'Riordan B; O'Connor P; Morgan SM; Lawlor PG; Lynch PB; Cronin M; Ross RP; Hill C
    Appl Environ Microbiol; 2007 Nov; 73(21):7103-9. PubMed ID: 17766459
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.